Department of Genetics and Genomic Sciences at Mount Sinai’s Post

Apoptosis, a crucial process in cell death regulation, can be disrupted in diseases like cancer and neurodegenerative disorders. Survivin, a protein inhibiting apoptosis pathways, is implicated in disease progression. A recent study explored Survivin's interactions using fragment luciferase technology, revealing insights into its role. Article: https://lnkd.in/gXwtGZB5 #Survivin #Apoptosis #Research #drugdiscovery #structuralbiology

Planning to attend the 5th Annual MarketsAndMarkets Biomarker and Companion Diagnostics Conference, March 7-8, 2024, in London? We’ll see you there! Meet with our team of spatial biology experts and see how our new 12-plex OmniVUE™ and U-VUE® panels and assay services can help provide a deeper understanding of the tumor microenvironment. From a single sample, simultaneously visualize up to 12 biomarkers of your choice using Ultivue’s InSituPlex® technology, and receive reliable, quantitative results that accelerate development of companion diagnostics. Schedule a meeting with us to discuss effective biomarker strategies and how you can gain even greater insights from precious tissue samples: https://hubs.ly/Q02mqg6z0 #SpatialBiology #Multiplexing #Pathology #ImmunoOncology #CancerResearch #Biomarkers #ClinicalTrials #TumorMicroenvironment #Immunotherapy #Immunofluorescence #TumorProfiling #ImmuneProfiling #CDx #CompanionDiagnostics

🎥 Exciting Advancements in MASH Research! 🌟 Explore the latest in metabolic dysfunction research using Cyagen's Composite Mouse Models. These models provide invaluable insights into obesity, diabetes, and liver conditions such as inflammation, fibrosis, and cancer. Discover how they aid in preclinical drug development, showcasing the positive effects of treatments like Rasum. Learn more about our models and collaboration opportunities. Let's advance liver disease research together! 🧬 #MASHresearch #biotech #liverdisease #Cyagen #researchinnovation #biotechnology #biosciences #researchimpact

🌟 Advancing #ExtracellularVesicle Research with a Novel Methodology 🌟 Erez Eitan and Olga Volpert's groups introduce an innovative approach to analyzing extracellular vesicle (EVs) surface proteins directly from plasma and other biofluids, bypassing the need for traditional isolation steps. This streamlined method employs a #multiplexedimmunoassay to simultaneously detect multiple EV markers, significantly improving both sensitivity and efficiency. The implications are profound: this technique not only accelerates #biomarker discovery but also enhances the potential for EV-based diagnostics in areas such as cancer, neurodegenerative disorders, and cardiovascular diseases. By simplifying complex workflows, this advancement takes us one step closer to integrating EVs as transformative tools in precision medicine and therapeutic development. 💡 This is a breakthrough for EV research, paving the way for more efficient and impactful diagnostic applications. 👉 Learn more about this process: https://lnkd.in/gw6wkP3w First author: Emma Tordoff #ExtracellularVesicles #BiomedicalResearch #Diagnostics #BiomarkerDiscovery #PrecisionMedicine #Innovation #Healthcare

The market size of #extracellularvesicle as #biomarkers constitutes approximately USD 140 million, accounting for 57% of the total market (Global Market Insights). New technologies for EV detection are in high demand, driven by their potential to enhance diagnostics and therapeutic monitoring in various medical fields. This new article by Erez Eitan and Olga Volpert introduces a promising advancement to analyze extracellular surface proteins directly from plasma and other biofluids. First author: Emma Tordoff https://lnkd.in/gVMbBeNK

Apoptosis is a crucial biological mechanism dictating the balance of cell death and survival. In doing so it plays a vital role in an organism's development, aging process, and defense mechanism to eliminate diseased or damaged cells from the body. If apoptosis is dysregulated, disease may arise. Increased apoptosis has been found in AIDs and neurodegenerative diseases such as Alzheimer’s, whereas reduced apoptosis has been associated with autoimmune disorders and cancer. However, it is now known that scientists can manipulate the process of apoptosis. Novel therapeutics and natural compounds that can control a cell's fate have been discovered and can be used to treat diseases where apoptosis has become dysregulated. To find out more read our blog linked below. https://lnkd.in/eB74_ca4 See also Biosynth's catalog featuring a range of critical raw materials for projects researching, diagnosing, and developing therapeutics for apoptosis-associated diseases. https://lnkd.in/eR9HAtdX #apoptosis #celldeath #therapeutics #cancer #neurodegenerativedisease #naturalproducts #researchproducts

This DNA Day, let's dive deeper into the fascinating world of cell-free DNA (cfDNA)! Cell-free DNA refers to small fragments of DNA that circulate freely in bodily fluids like blood, urine, or saliva. cfDNA is released into the bloodstream through various natural processes. Excitingly, it offers a noninvasive and versatile approach to understanding human health and disease. At Aqtual, Inc., we're leveraging the power of cfDNA to develop a novel catalog of tissue-, disease- and drug-specific targets in multiple therapeutic areas. By studying these fragments, we can uncover valuable insights into inflammatory conditions, oncology, immunology, cardiovascular diseases, metabolic diseases, and neurological conditions. For us, every day is DNA Day, but today, we’re excited to be joining everyone in celebrating all those As, Cs, Ts, and Gs! #DNADay24 #cfDNA #MolecularDiagnostics #HealthcareInnovation #PrecisionMedicine

On World Cancer Day, we mark the final year of the 'Close the Care Gap' campaign, urging governments to address disparities in cancer services. In 2024, an estimated 2,001,140 new cancer cases and 611,720 deaths are projected in the U.S. While mortality rates have declined, challenges persist, with rising incidence for 6 of the top 10 cancers. Proud of our portfolio companies, Foresee Genomics LTD and Nevia bio, for contributing innovative solutions. Foresee uses next-gen sequencing for accessible personalized cancer diagnosis, while Nevia transforms women’s health with an early detection platform for ovarian cancer biomarkers. Learn more: https://lnkd.in/daKzyf2 #CancerAwareness #EarlyDetection #WorldCancerDay #CloseTheCareGap Dan Shwarzman, Dalia Mor, Zvika Shinar, Maura Rosenfeld, Judith Hammerschlag Grynbaum Foresee Genomics LTD: Roi Feingersch Nevia bio: Inbal Zafir-Lavie, Valeria Miller, Shiri Blumenfeld-Kan, Zohar Shnaider, Shlomit Yehudai-Reshef, PhD

Parkinson's Discovery Suggests We May Already Have an FDA-Approved Treatment https://lnkd.in/ezwjYmhk Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for Parkinson's disease from cell-to-cell in the brain. Promisingly, an FDA-approved cancer drug that targets another protein called Lag3 – which interacts with Aplp1 – blocks the spread in mice, suggesting a potential therapy may already exist. In a new paper, an international team of scientists describes how the two proteins work together to help harmful alpha-synuclein protein clumps get into brain cells. "Now that we know how Aplp1 and Lag3 interact, we have a new way of understanding how alpha-synuclein contributes to the disease progression of Parkinson's disease," says Xiaobo Mao, a neuroscientist from Johns Hopkins University in the US. "Our findings also suggest that targeting this interaction with drugs could significantly slow the progression of Parkinson's disease and other neurodegenerative diseases." #parkinson

Pleased to report a new #ORIEN multi-institutional study led at the University of Colorado published in Cancers MDPI providing insights on the unique clinical characteristics and genetic mutations of renal cell carcinoma (#RCC) in patients with advanced chronic kidney disease (#ACKD). Key findings include:    ▪ A higher likelihood of RCC in males with ACKD.  ▪ Earlier stage RCC diagnosis in ACKD patients.  ▪ Lower rates of BAP1 mutations, suggesting a different mutational driver in ACKD-related RCC.    This study underscores the importance of understanding the BAP1-independent mechanisms contributing to RCC in ACKD patients and further supports BAP1 loss as a prognostic marker of aggressive disease.      Learn more: https://lnkd.in/eu8yDazB    #OncologyResearch #CollaborativeScience